Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025DrugsOpen Access

Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review

View Full Paper
Ask AI
Bookmark
Share

Authors

CBCharlotte BeaudartCBChristian BrabantMAMajed S. Alokail

Discussion

Loading...

Member takes

Overview

Umbrella review synthesizes safety evidence of celecoxib in chronic musculoskeletal disorders, highlighting gastrointestinal and cardiovascular outcomes.

Key Points

  • Celecoxib is associated with a lower risk of gastroduodenal ulcers compared to non-selective NSAIDs, indicating better gastrointestinal safety.
  • Of 16 systematic reviews, 14 were deemed to have low quality, raising concerns about the reliability of the findings relating to celecoxib safety.
  • The evidence for cardiovascular safety with celecoxib aligns closely with non-selective NSAIDs, but one meta-analysis suggested reduced cardiovascular mortality.
  • Limited evidence on all-cause mortality indicates celecoxib may be safer than non-selective NSAIDs, especially concerning renal adverse events.

Cite This Study

Beaudart et al. (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d6478865ahttps://doi.org/10.1007/s40265-025-02234-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials2025
  2. 2Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis2025
  3. 3Anti-Inflammatory Mechanisms of Selective Cox-2 Inhibitors: A Preclinical Analysis2025
  4. 4Advancing Pain Management: Exploring New Formulations of Celecoxib2025
  5. 5Mechanisms Involved in the Adverse Cardiovascular Effects of Selective Cyclooxygenase-2 Inhibitors2025